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Abstract
Objectives The objective was to examine the eVects of
testosterone administration on symptom scores of lower
urinary tract symptoms (LUTS).
Methods The literatures on the epidemiological associa-
tion between the metabolic syndrome, erectile failure and
(LUTS) were reviewed.
Results In men with the metabolic syndrome and erectile
failure, often lower-than-normal testosterone levels are
found. This is less clear for men with LUTS, but the rela-
tionship between testosterone and LUTS might be indirect
and based on the association of the metabolic syndrome
with an overactivity of autonomic nervous system. This
overactivity may play a key role in increasing the severity
of LUTS above an intrinsic basal intensity that is deter-
mined by the genitourinary factors in aging men. Androgen
receptors are present in the epithelium of the urethra and the
bladder. Testosterone may play a role in the reXex activity of
the autonomic nervous system in the pelvis, or may interact
with postsynaptic non-genomic receptors suppressing
detrusor activity. Human neurons in the wall of the bladder
contain nitric oxide synthase. Similar to the penis, testoster-
one has an impact on nitric oxide synthase.
Conclusions Some studies investigating the eVects of nor-
malizing testosterone levels in elderly men have found a posi-
tive eVect on variables of the metabolic syndrome and,
simultaneously, on scores of the International Prostate Symp-
toms Score (IPSS) which is worthy of further investigation in
randomized, controlled and suYciently powered clinical trials.
Keywords Lower urinary-tract symptoms · Aging · 
Testosterone · Phospho-diesterase type 5
Introduction
Over the past two decades, it becomes clear that many age-
related health problems of men, hitherto treated by diVerent
medical disciplines, are actually inter-related and require a
more integrative approach to the health situation of the
aging male. At the epidemiological level, an association
between central obesity in adulthood, the metabolic syn-
drome, erectile failure and lower urinary-tract symptoms
(LUTS) has been established [1]. A common denominator
of the above ailments is lower-than-normal testosterone
levels occurring in a signiWcant proportion of elderly men
[2]. The decline of serum testosterone may be demonstrable
over relatively short periods of observation. Throughout a
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4-year follow-up in elderly patients with erectile dysfunc-
tion, there was a steady decrease in testosterone levels [3].
Many studies have tried to establish a relationship
between sex steroids and benign prostate hyperplasia, and a
few studies have analyzed the relationship between circu-
lating testosterone and LUTS symptoms. One study found
that hypogonadism was seen in approximately one-Wfth of
elderly men with LUTS, but it had no impact on symptom
status [4]. Another study found a relationship between
symptoms of LUTS and plasma total and bioavailable tes-
tosterone but this relationship disappeared after statistical
adjustment for age [5]. No consistent correlations were
found between total and calculated free testosterone and
symptoms of LUTS in another study, but there was a rela-
tionship with androstanediolglucuronide, a metabolite of
dihydrotestosterone and with estradiol [1]. A very recent
study found a relationship between circulating androgens
and bladder outlet obstruction. Low T levels in clinical
bladder outlet obstruction correlated negatively with detru-
sor pressure at maximum Xow and at urethral closure while
promoting detrusor overactivity [6].
Overall it has been diYcult to relate plasma testosterone
to LUTS, but it is of note that, within certain limits of tes-
tosterone levels, the signs and symptoms of testosterone
deWciency in men do not relate in a uniform pattern to tes-
tosterone concentrations [7] which may be (in part)
explained by properties of the androgen receptor (the CAG
repeat polymorphism in exon 1 of the androgen receptor
gene) [8]. Nevertheless, it must be concluded that so far no
clear relationship between LUTS and testosterone could be
demonstrated. It could well be that the detrimental eVects of
testosterone deWciency and the beneWts of testosterone
treatment are indirect. The following sections will discuss
the various elements of the urodynamic system on which T
impacts. This is graphically presented in Fig. 1. Whether
these elements are interrelated remains to be determined.
The relationship between the metabolic syndrome 
and LUTS
A recent study trying to explain the epidemiological rela-
tionship between the metabolic syndrome and LUTS
hypothesized that the metabolic syndrome is associated
with an overactivity of the autonomic nervous system [9,
10] for which hyperinsulinemia, a key element of the meta-
bolic syndrome might be responsible [9, 10]. This overac-
tivity of the autonomic nervous system is supposedly not
responsible for the development of LUTS, but plays a key
role in increasing the severity of LUTS above an intrinsic
basal intensity that is determined by the genitourinary ana-
tomical/pathophysiological characteristics of other ailments
leading to LUTS [11, 12]. Another recent study provided
evidence that stress conditions could be associated with the
development and aggravation of prostatic disease. It was
found that body mass index, and age, greater diastolic
blood pressure reactivity were associated with a greater
transition zone volume, greater total prostate gland volume,
greater postvoid residual bladder volume, and more severe
LUTS [13]. InXammatory inWltrates are frequently found in
and around nodules in benign prostate hyperplasia (BPH)
and in symptomatic BPH [14]. The presence of the meta-
bolic syndrome might be a mediator of this association
because it is associated with elevated serum C-reactive pro-
tein concentration, a non-speciWc marker of inXammation
[15], thus linking the metabolic syndrome to LUTS and
Fig. 1 Potential sites of action 
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elevated circulating C-reactive protein concentrations
might be an indicator of intraprostatic inXammation in
symptomatic BPH [14, 15]. (Central) obesity is a hallmark
of the metabolic syndrome of which the other components
are dyslipidemia, hypertension, impaired glucose metabo-
lism, with insulin resistance and diabetes type 2. Particu-
larly if poorly controlled, there is a signiWcant association
between low level of total testosterone or DHEA-S and
indices of poorly controlled type 2 diabetes [16].
Insulin resistance is associated with hyperinsulinemia
and insulin, particularly in excess, has due to its biochemi-
cal similarities with insulin-like growth factor, growth pro-
moting properties [17]. This might be a factor in the growth
of the prostate in aging men [18]. It has become clear that
normal levels of T improve insulin resistance [19].
All the above-mentioned elements of the metabolic syn-
drome are conducive to the development not only of erec-
tile dysfunction but also of LUTS. Risk factors and medical
co-morbidities of erectile dysfunction were prevalent
among patients with LUTS [20] (El-Sakka 2006b) and it is,
therefore, not surprising that a larger number of studies
have established a relationship between LUTS and erectile
dysfunction [21–23], particularly since an underlying vas-
cular association between LUTS and erectile dysfunction
could be demonstrated [24].
As indicated earlier, with a more integrative approach to
the ailments of the aging male, the age-related decline of
plasma testosterone levels has been found to be a feature of
erectile failure and central obesity in elderly men with
proven successes of administration of testosterone to cor-
rect lower-than-normal levels [25–29]. So, it is time to
review the relationship between late onset hypogonadism
(LOH) and LUTS, which like the other ailments mentioned
earlier, manifest themselves concurrently in the lives of eld-
erly men.
Potential eVects of testosterone on the urinary tract
Testosterone itself might not be the ‘prime mover’ of the
eVects of testosterone on those structures of the urinary
tract anatomically and functionally related to LUTS. The
indirect relation could obscure an interrelation between cir-
culating levels of testosterone and symptoms of LUTS at a
statistically signiWcant level which nevertheless is biologi-
cally plausible.
Androgen receptors have been found to be present to a
large extent in the epithelial cells of the urethra and the
bladder [30]. In another study, the role of testosterone and
its metabolites on maintaining the reXex activity in the pel-
vic part of the autonomic nervous system could be demon-
strated in rats [31]. Others have postulated the inXuence of
testosterone on postsynaptic non-genomic receptors which
are suppressing detrusor activity [32,  33]. Castration
resulted in signiWcant alterations in the activities of citrate
synthase-thapsigargin sensitive Ca(2+) ATPase [sarco/
endoplasmic reticulum Ca(2+)ATPase (SERCA)], and cho-
line acetyl-transferase as markers for mitochondrial func-
tion, sarcoplasmic reticular calcium storage and release,
and cholinergic nerve function, in the bladder body, ure-
thra, and corpora [34].
Not only the penis but also in other parts of the urogeni-
tal tract nitric oxide (NO) acts as a non-adrenergic non-cho-
linergic neurotransmitter in the urogenital tract and the
action of testosterone on the urogenital tract may be medi-
ated by this system [35]. There is increasing evidence for a
link between ED and LUTS, the metabolic syndrome, pel-
vic atherosclerosis with its associated rho-kinase activation/
endothelin pathway, the NOS/NO theory, and the auto-
nomic hyperactivity [36]. Studies treating one condition
(e.g., ED) and measuring the impact on the other (e.g.,
LUTS) should further contribute to support this common
link. But as yet it is not possible to provide a comprehen-
sive picture of the impact of testosterone (and its deW-
ciency) on the lower urinary tract.
Nitric oxide production is androgen dependent 
in urinary tract
Nitric oxide (NO) acting as a non-adrenergic non-choliner-
gic neurotransmitter is not only present in genital structures
but also in the urinary tract and exerts a smooth muscle
relaxing eVect in both animals and humans. NO is a media-
tor not only of erection but also of dilatation of the bladder
neck and urethra. A study in the human indicated that NO is
an important nerve-induced mediator of erection and the
micturition reXex, but NO may also be involved in several
other functions in the human urogenital tract [37]. In
humans, 72–96% of neurons in the wall of the bladder
appear to contain nitric oxide synthase. Nitric oxide syn-
thase-immunoreactive nerve terminals provide a moderate
innervation to the detrusor muscle of the bladder body, and
a denser innervation to the urethral muscle. Nitric oxide
may be an inhibitory transmitter involved in the relaxation
of the bladder neck [38]. Cyclic nucleotides are important
secondary messengers of nitric oxide involved in modulat-
ing the contractility of various smooth muscles.
Phosphodiesterases (PDE) play important roles in this
process by modulating the levels of cyclic nucleotides and
their duration of action. Their presence in the urinary blad-
der could be identiWed in studies of the rat [39] and the
human [40].
Phosphodiesterase 5 is an inhibitor of nitric oxide/cGMP
signaling. A recent study, investigating PDE5 expression
and activity in the human bladder, elegantly demonstrated362 World J Urol (2008) 26:359–364
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that PDE5 regulates smooth muscle tone of the bladder.
VardenaWl appeared to block PDE5 activity, and therefore,
may be a possible therapeutic option for bladder dysfunc-
tion by ameliorating irritative lower urinary-tract symp-
toms. The study also found that castration decreased, and
testosterone supplementation restored, PDE5 gene expres-
sion in rat bladder [35].
As a further substantiation of the role of androgens in
the urogenital tract, NO-synthase in an earlier study had
appeared to be androgen dependent in the urogenital tract
of the rat [41]. Meanwhile a large number of clinical studies
have convincingly shown that phosphodiesterase inhibitors
have a beneWcial eVect on LUTS [36, 42–48].
From the above, it would appear that androgens are not
only essential for the formation of a male urogenital tract
prenatally and its adult development during puberty but
that, similar to erectile tissue in the penis, maintenance of
the functionality of the urinary tract in adult life is sub-
served by androgens. It could be that declining testosterone
production with aging contributes to the discomfort elderly
men experience with micturition.
EVects of testosterone on LUTS
The Wrst mention of eVects of testosterone on bladder func-
tion was reported by Holmang et al. [49]  Wnding an
increase in peak urinary Xow and mean urine volume
voided in a testosterone-treated group of men compared to
placebo treatment. But, in recent years there has been only
preliminary evidence that men with LUTS beneWt from
treatment with testosterone, only in the form of abstracts
awaiting peer-reviewed publication. The Wrst data on this
subject have shown that normalization of testosterone lev-
els has a positive eVect on LUTS in men with BPH and
LOH [50]. A recent presentation conWrmed the positive
eVects of testosterone treatment on bladder functions by
increasing bladder capacity and compliance and decreasing
detrusor pressure at maximal Xow in men with SLOH [51].
The results of another pilot study [52] also showed positive
eVect of testosterone undecanoate therapy on LUTS in men
with LOH.
In a series of papers, we have reported the eVects of tes-
tosterone administration on a number of variables relating
to the ailments of the aging male. The studies were not spe-
ciWcally designed to investigate the eVects of testosterone
administration to elderly men on symptoms of LUTS, but
eVects of testosterone treatment on the International Pros-
tate Symptoms Score (IPSS) were recorded. In the Wrst
study, the eVects of administration of parenteral testosterone
undecanaote (TU) over 12 months were analyzed [53].
There were positive clinical eVects of administration of TU
on the IPSS and also on parameters of the metabolic
syndrome, progressive over the 12 month study period.
Since the eVects were progressive over the 12 months of the
study, it is likely that the eVects take time to occur follow-
ing testosterone administration. In the second study the
eVects of testosterone gel in a dose of 50 mg/day over
9 months on symptoms of LOH were compared to those of
parenteral TU [54]. The higher plasma levels of T generated
with TU than with T gel (50 mg/day) were more eVective in
reducing the scores on the IPSS, probably indicating that
there is a relationship between plasma levels of testosterone
and their eVects on LUTS. The third study investigated the
eVects testosterone gel in a dose of 50 mg/day over
9 months which had a positive eVect on scores of the IPSS.
Subsequently, these men shifted their testosterone treat-
ment to administration of parenteral testosterone undecana-
ote (TU) [54). There were positive clinical eVects of
administration of T gel on the IPSS and also on parameters
of the metabolic syndrome, and there was a signiWcant fur-
ther improvement of the IPSS when TU was administered
after 9 months of administration of T gel when plasma T
levels increased to higher levels than with T gel.
It is obvious that better designed placebo-controlled,
randomized, studies are needed to explore the potential
relationship between T and LUTS and the potential of a
therapeutic eVect of T in cases of T deWciency. It is impor-
tant to uncover whether there is a threshold eVect, so men
with a range of baseline T levels should be included. Fur-
ther, the eVect of T in men with distinctly diVerent IPSS
should be investigated for a potential salutary eVect of T
administration. It would also be signiWcant to explore
whether normalization of plasma T has an adjunctive thera-
peutic eVect to the more established pharmacological treat-
ment modalities of LUTS. Urodynamic assessment may
provide greater insight into the potential mode of action of
T on LUTS. The potential beneWcial eVects of T on LUTS
may well be indirect, and therefore suYciently powered
studies are required to convincingly demonstrate an eVect
of T on LUTS.
Conclusions
It is common for aging men to experience urinary problems
subsumed under the umbrella term LUTS. LUTS is an
important determinant of quality of life [55]. Several other
ailments of the aging male, such as erectile dysfunction and
the metabolic syndrome appear to be related to circulating
levels of testosterone. At an epidemiological level this rela-
tionship has been more diYcult to demonstrate for LUTS
and the relationship between LUTS and circulating levels
of testosterone may be indirect. The relationship between
the metabolic syndrome and LUTS may be based on the
fact that the metabolic syndrome is associated with an over-World J Urol (2008) 26:359–364 363
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activity of autonomic nervous system [9]. This overactivity
of the autonomic nervous system may play a key role in
increasing the severity of LUTS above an intrinsic basal
intensity that is determined by the genitourinary anatomi-
cal/pathophysiological characteristics of other ailments
leading to LUTS [12, 13].
At present, the targets for a potentially beneWcial eVect
of testosterone on the urinary system can be only sketchily
described,
Some studies investigating the eVects of restoration of
plasma testosterone levels in elderly men to normal found a
positive eVect on variables of the metabolic syndrome and
scores of the IPSS. The evidence that testosterone treatment
has a beneWcial eVect on LUTS must be regarded as prelim-
inary, but in view of the impact LUTS has on the lives of
elderly men [55], this relationship is worthy of further
investigation.
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